Ventus has an emerging pipeline of innovative medicines to treat acute and chronic inflammatory and immune-related diseases. We are focusing on developing small-molecule medicines to target proteins in the inflammasome and nucleic acid sensing signaling pathways. We have multiple programs in the hit to lead or lead optimization phase and are pursuing a broad pipeline of additional targets.